Searched for
KIRTI GANORKAR
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Sun Pharma launches Ilumya for psoriasis treatment in IndiaSun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....
- Sun Pharma brings global psoriasis drug ILUMYA to Indian marketSun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...
- Kirti Ganorkar: Why the veteran insider is the right dose for Sun PharmaKirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, wh...
- Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the BoardSun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi...
- Sun Pharma scouting for innovative therapies to boost India businessApproved by the Indian drug regulator in May 2023, sovateltide can be administered within 24 hours for the treatment of ischemic stroke, al...
- Sun Pharma inks pact with Bayer to sell drug for chronic kidney diseaseSun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights...
- Sun Pharma to market Zydus' novel anti-CKD drug desidustat in India“The addition of RYTSTAT further strengthens our nephrology portfolio in India," said Kirti Ganorkar, CEO - India Business, Sun Pharma.
- Sun Pharma launches novel therapy for dry eye disease in IndiaDED is caused when the quantity or quality of tears fails to keep the surface of the eye properly lubricated, and associated with symptoms ...
- Sun Pharma plans to focus on market share, sales in bid to outdo rivalsAs part of the strategy to stay ahead of its rivals in the highly fragmented domestic formulation business, Sun Pharma has embarked on majo...
- Sun Pharma to expand field force in India by 10 pc this fiscal"The field force expansion done in FY21 has met with good success and considering the current market conditions, we will be undertaking a f...
- Sun Pharma enters licensing pact with Lundbeck to launch novel anti-depressant pill in IndiaVortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
- Pharma, healthcare industry looks to sustain momentum in 2022Listing out difficulties for the domestic pharma industry, Sun Pharma CEO (India Business) Kirti Ganorkar said that currency fluctuations, ...
- Sun Pharma says gearing up to launch COVID drug molnupiravirThe company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...
- Sun Pharma, NIV join hands to fight zika, chikungunya, dengueUnder the agreement, Sun Pharma will provide drug molecules to NIV for testing against zika, chikungunya and dengue in model systems, the c...
- Sun Pharma to acquire oncology product from Novartis for $175 mnThe agreement has been signed between subsidiaries of both the companies and will close following anti-trust clearance and further closing ...
- SPARC, Sun Pharma climb on licensing agreementThe deal will make the company eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPS...
Load More
